Production (Stage)
Tonix Pharmaceuticals Holding Corp.
TNXP
$28.93
$2.539.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.81% | -11.47% | -11.76% | -22.12% | 15.59% |
| Total Depreciation and Amortization | -33.26% | -19.39% | 9.87% | 53.48% | 111.62% |
| Total Amortization of Deferred Charges | -27.29% | -- | 252.94% | -- | -- |
| Total Other Non-Cash Items | 2,839.01% | 468.08% | 536.13% | 488.70% | -79.33% |
| Change in Net Operating Assets | -71.88% | 16,600.00% | -105.12% | 23.10% | 27.06% |
| Cash from Operations | 30.85% | 40.27% | 32.69% | 28.30% | 13.26% |
| Capital Expenditure | 99.57% | 98.48% | 95.42% | 87.67% | 86.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -99.29% | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | 100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 99.93% | 99.59% | 98.35% | 96.71% | 20.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4,906.38% | -- | -- | -- | -- |
| Issuance of Common Stock | 1,002.40% | 577.42% | 237.03% | -25.89% | -75.59% |
| Repurchase of Common Stock | -- | -- | 100.00% | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -162.94% | -151.78% | 274.17% | 291.47% | 1,416.09% |
| Cash from Financing | 286.19% | 269.34% | 2,882.59% | 783.88% | -24.46% |
| Foreign Exchange rate Adjustments | 96.15% | 106.15% | 50.00% | 63.24% | 71.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 293.99% | 178.03% | 116.04% | 86.26% | 6.12% |